 Stealth BioTherapeutics Corp NASDAQ: MITO presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology. TDP-43 pathology plays a significant role in amyotrophic lateral sclerosis ALS and frontotemporal dementia FTD. 